Systems medicine, which applies a mechanism-based approach to disease for identifying therapeutic targets beyond a hypothesis-driven approach, has evidenced the altered NRF2 interactome in advanced cancers and neoplasms [11]. Here, NFE2L2 is linked to cancer.